NRP1 function-blocking mAbs have been developed for its three extra-cellular domains, allowing for specific blockade of its co-receptor functions [139]; since NRP1 is extensively expressed on tumor vasculature, where over-expression promotes tumor progression and angiogenesis, NRP1 has proven particularly valuable as a target for anti-angiogenic therapies [80]. Here, NRP1 is linked to neoplasm.